Mereo BioPharma Group plc (MREO) shareholders
Close on Nov 18, 2026Market cap $46.20MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Rosen | 108,486,735 | – | 13D (active) amendment | Jun 17, 2024 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (8.40%), EcoR1 Capital Fund Qualified, L.P. (7.80%) | 66,844,275 | 8.40% | 13G (passive) amendment | Mar 31, 2026 |
| 683 Capital Management, LLC Joint filing with 683 Capital Partners, LP (8.18%), Ari Zweiman (8.18%) | 65,083,815 | 8.18% | 13G (passive) | Dec 29, 2025 |
| Michael P. Rubin | 54,521,000 | 6.90% | 13G (passive) | Jun 4, 2025 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (5.62%), Robert Atchinson (5.62%) | 43,575,065 | 5.62% | 13G (passive) amendment | Dec 31, 2024 |
| Patrick J. Heron Joint filing with James N. Topper (5.10%) | 40,349,315 | 5.10% | 13G (passive) | Apr 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MREO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 15,307,347 | 1.92% | $4.86M | – | 0.04% |
| 683 Capital Management, LLC | 11,777,856 | 1.48% | $3.74M | −222,144 | 0.18% |
| Bank Of America Corp /De/ | 8,195,281 | 1.03% | $2.60M | −6 | 0.00% |
| Defilade Capital Management, L.P. | 7,558,756 | 0.95% | $2.40M | – | 0.32% |
| Newtyn Management, LLC | 3,000,000 | 0.38% | $953.10K | −4,079,056 | 0.12% |
| Tejara Capital Ltd | 2,037,520 | 0.26% | $647.32K | – | 0.27% |
| UBS Group AG | 1,447,627 | 0.18% | $460.35K | −42,501 | 0.00% |
| Two Sigma Investments, LP | 1,319,241 | 0.17% | $419.12K | +1,131,402 | 0.00% |
| EcoR1 Capital, LLC | 1,000,000 | 0.13% | $317.70K | −12,368,855 | 0.02% |
| Jane Street Group, LLC | 774,944 | 0.10% | $246.20K | +634,971 | 0.00% |
| Ishara Investments LP | 768,750 | 0.10% | $244.23K | New | 0.18% |
| Wealthspire Advisors, LLC | 765,000 | 0.10% | $243.04K | −31,036 | 0.00% |
| Citadel Advisors LLC | 444,158 | 0.06% | $141.11K | New | 0.00% |
| Rangeley Capital, LLC | 329,200 | 0.04% | $104.59K | – | 0.10% |
| Susquehanna International Group, Llp | 213,270 | 0.03% | $67.76K | +17,350 | 0.00% |
| Marshall Wace, Llp | 179,884 | 0.02% | $57.56K | −507,103 | 0.00% |
| XTX Topco Ltd | 174,481 | 0.02% | $55.43K | +90,012 | 0.00% |
| Group One Trading, L.P. | 167,515 | 0.02% | $53.22K | −168,312 | 0.00% |
| State Street Corp | 134,772 | 0.02% | $42.82K | +1,393 | 0.00% |
| Nomura Holdings Inc | 104,361 | 0.01% | $33.16K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 57M | 7.1% | 15 / 13 | 12 / 17 | 4M | 22M |
| Q1 2026 | 63 | 75M | 9.4% | 15 / 15 | 16 / 22 | 34M | 20M |
| Q4 2025 | 70 | 62M | 7.8% | 22 / 15 | 20 / 35 | 30M | 68M |
| Q3 2025 | 84 | 100M | 12.6% | 14 / 23 | 23 / 16 | 16M | 14M |
| Q2 2025 | 86 | 99M | 12.4% | 12 / 31 | 19 / 16 | 8M | 20M |
| Q1 2025 | 90 | 111M | 13.9% | 13 / 27 | 21 / 14 | 16M | 20M |
| Q4 2024 | 91 | 115M | 14.4% | 21 / 19 | 27 / 7 | 15M | 5M |
| Q3 2024 | 77 | 106M | 13.2% | 11 / 20 | 22 / 12 | 12M | 7M |
| Q2 2024 | 79 | 101M | 12.6% | 15 / 20 | 27 / 15 | 28M | 14M |
| Q1 2024 | 80 | 87M | 10.9% | 28 / 24 | 12 / 11 | 24M | 15M |
| Q4 2023 | 64 | 79M | 9.8% | 17 / 19 | 13 / 9 | 12M | 4M |
| Q3 2023 | 56 | 71M | 8.8% | 10 / 13 | 15 / 6 | 15M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held MREO in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MREO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 134,772 | 0.02% | $42.82K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 92,534 | 0.01% | $31.83K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 14,500 | 0.00% | $4.61K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Denise Scots-Knight | Chief Executive Officer, Director | 808,921 | 0.10% | Feb 2, 2026 |
| Alexandra Hughes-Wilson | See Remarks | 134,483 | 0.02% | Feb 2, 2026 |
| Charles Sermon | General Counsel | 219,061 | 0.03% | Feb 2, 2026 |
| John A. Lewicki | Chief Scientific Officer | 92,826 | 0.01% | Feb 2, 2026 |
| Christine Ann Fox | Chief Financial Officer | 89,285 | 0.01% | Feb 2, 2026 |
| Pierre Jacquet | Director | – | – | Feb 27, 2026 |
| Anders Ekblom | Director | 37,940 | 0.00% | Feb 27, 2026 |
| Jeremy Bender | Director | 12,550 | 0.00% | Feb 27, 2026 |
| Daniel Shames | Director | – | – | Feb 27, 2026 |
| Deepika Pakianathan | Director | 1,825 | 0.00% | Feb 27, 2026 |
| Michael S. Wyzga | Director | 25,050 | 0.00% | Feb 27, 2026 |
| Annalisa Jenkins | Director | – | – | Feb 27, 2026 |
| Marc J. Yoskowitz | Director | – | – | Feb 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John A. Lewicki Chief Scientific Officer | Sep 13, 2024 | Sale | −10,937 | $4.22 | $46.15K | 78,630 |
| Christine Ann Fox Chief Financial Officer | Sep 13, 2024 | Sale | −19,158 | $4.22 | $80.85K | 89,285 |
| Charles Sermon General Counsel | Sep 13, 2024 | Sale | −20,946 | $4.22 | $88.39K | 219,061 |
| Alexandra Hughes-Wilson See Remarks | Sep 13, 2024 | Sale | −16,304 | $4.22 | $68.80K | 134,483 |
| Alexandra Hughes-Wilson See Remarks | Sep 13, 2024 | Sale | −84,008 | $4.22 | $354.51K | 50,475 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 13, 2024 | Sale | −60,046 | $4.22 | $253.39K | 808,921 |
| John A. Lewicki Chief Scientific Officer | Sep 12, 2024 | Sale | −5,212 | $4.47 | $23.30K | 89,567 |
| Christine Ann Fox Chief Financial Officer | Sep 12, 2024 | Sale | −9,128 | $4.47 | $40.80K | 108,443 |
| Charles Sermon General Counsel | Sep 12, 2024 | Sale | −9,980 | $4.47 | $44.61K | 240,007 |
| Alexandra Hughes-Wilson See Remarks | Sep 12, 2024 | Sale | −7,769 | $4.47 | $34.73K | 190,816 |
| Alexandra Hughes-Wilson See Remarks | Sep 12, 2024 | Sale | −40,029 | $4.47 | $178.93K | 150,787 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 12, 2024 | Sale | −28,611 | $4.47 | $127.89K | 868,967 |
| Christine Ann Fox Chief Financial Officer | Sep 11, 2024 | Option exercise | +60,000 | – | – | 117,571 |
| Denise Scots-Knight Chief Executive Officer, Director | Sep 11, 2024 | Option exercise | +188,060 | – | – | 897,578 |
| John A. Lewicki Chief Scientific Officer | Sep 11, 2024 | Option exercise | +46,000 | – | – | 94,779 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +75,000 | $1.01 | $75.75K | 242,881 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +40,000 | – | – | 74,548 |
| Alexandra Hughes-Wilson See Remarks | Sep 11, 2024 | Option exercise | +93,333 | $1.40 | $130.67K | 167,881 |
| Charles Sermon General Counsel | Sep 11, 2024 | Option exercise | +65,600 | – | – | 249,987 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +1,825 | $3.00 | $5.48K | 1,825 |
| Deepika Pakianathan Director | Aug 22, 2024 | Sale | −105,244 | $4.43 | $466.23K | 0 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +6,492 | $1.84 | $11.95K | 8,317 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +38,953 | $1.31 | $51.03K | 59,688 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +12,418 | $2.72 | $33.78K | 20,735 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +2,071 | $3.87 | $8.01K | 105,244 |
| Deepika Pakianathan Director | Aug 22, 2024 | Option exercise | +43,485 | $0.94 | $40.88K | 103,173 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 26, 2024 | Sale | −92,273 | $3.39 | $312.81K | 709,518 |
| Charles Sermon General Counsel | Jun 26, 2024 | Sale | −32,187 | $3.39 | $109.11K | 184,387 |
| Christine Ann Fox Chief Financial Officer | Jun 26, 2024 | Sale | −29,439 | $3.39 | $99.80K | 57,571 |
| John A. Lewicki Chief Scientific Officer | Jun 26, 2024 | Sale | −16,808 | $3.39 | $56.98K | 48,779 |
| Alexandra Hughes-Wilson See Remarks | Jun 26, 2024 | Sale | −22,968 | $3.39 | $77.86K | 34,548 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 25, 2024 | Sale | −40,712 | $3.69 | $150.23K | 801,791 |
| Charles Sermon General Counsel | Jun 25, 2024 | Sale | −14,202 | $3.69 | $52.41K | 216,574 |
| Christine Ann Fox Chief Financial Officer | Jun 25, 2024 | Sale | −12,990 | $3.69 | $47.93K | 87,010 |
| John A. Lewicki Chief Scientific Officer | Jun 25, 2024 | Sale | −7,416 | $3.69 | $27.37K | 65,587 |
| Alexandra Hughes-Wilson See Remarks | Jun 25, 2024 | Sale | −10,134 | $3.69 | $37.39K | 57,516 |
| Charles Sermon General Counsel | Jun 21, 2024 | Option exercise | +98,400 | – | – | 230,776 |
| Alexandra Hughes-Wilson See Remarks | Jun 21, 2024 | Option exercise | +60,000 | – | – | 67,650 |
| Denise Scots-Knight Chief Executive Officer, Director | Jun 21, 2024 | Option exercise | +282,090 | – | – | 842,503 |
| John A. Lewicki Chief Scientific Officer | Jun 21, 2024 | Option exercise | +69,000 | – | – | 73,003 |
| Christine Ann Fox Chief Financial Officer | Jun 21, 2024 | Option exercise | +90,000 | – | – | 100,000 |
| Jeremy Bender Director | Jun 17, 2024 | Award | +12,550 | $3.99 | $50.07K | 12,550 |
| Michael S. Wyzga Director | Jun 17, 2024 | Award | +25,050 | $3.99 | $99.95K | 25,050 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Sale | −50,082 | $2.94 | $147.24K | 32,568 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Option exercise | +75,000 | $1.01 | $75.75K | 82,650 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Tax withholding | −42,983 | $1.40 | $60.18K | 7,650 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Sale | −50,350 | $2.99 | $150.55K | 58,633 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Option exercise | +93,333 | $1.40 | $130.67K | 100,983 |
| Alexandra Hughes-Wilson See Remarks | May 22, 2024 | Tax withholding | −24,918 | $1.01 | $25.17K | 7,650 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mereo BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 107,319 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John A. Lewicki Officer | Sep 12, 2024 | 16,149 | $75.25K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Sep 12, 2024 | 88,657 | $413.14K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Charles Sermon Officer | Sep 12, 2024 | 30,926 | $144.12K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Sep 12, 2024 | 28,286 | $131.81K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Alexandra Hughes-Wilson Officer | Sep 12, 2024 | 148,110 | $690.19K | Sep 12, 2024 | Same Day Cashless Exercise and Sale |
| Deepika Pakianathan Director | Aug 22, 2024 | 105,244 | $466.21K | Aug 22, 2024 | Exercise of option under a registered plan |
| Alexandra Hughes-Wilson Officer | Jun 24, 2024 | 33,102 | $131.75K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Jun 24, 2024 | 146,284 | $582.21K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Charles Sermon Officer | Jun 24, 2024 | 51,028 | $203.09K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Jun 24, 2024 | 46,672 | $185.75K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| John A. Lewicki Officer | Jun 24, 2024 | 26,647 | $106.06K | Jun 25, 2024 | Same Day Cashless Exercise and Sale |
| Christine Ann Fox Officer | Jun 20, 2024 | 46,672 | $185.75K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| Alexandra Hughes-Wilson Officer | Jun 20, 2024 | 33,102 | $131.75K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| John A. Lewicki Officer | Jun 20, 2024 | 26,647 | $106.06K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
| Denise Scots-Knight Officer, Director | Jun 20, 2024 | 146,284 | $582.21K | Jun 21, 2024 | Same Day Cashless Exercise and Sale |
See a number that looks wrong?